IP, these were my thoughts exactly. Going forward there is no real risk to the buyer. If there was infringement, JnJ will have to continue to defend it.
Could you explain how you came to the conclusion that the outcome of the current infringement case (as yet unresolved ) has "little or no bearing on the sale of the Lifescan franchise" when a significant portion of the revenues are derived from sales of the strips whose patents are in question?
I am in no way implying that DECN is on the verge of winning $400 million based on this case. The current share price of 0.05 says the market agrees. My point is that if there was historical infringement by JNJ of a patent that was valid at that time it would seem to imply that going forward they may not have the same leverage/tools available to them to maintain market dominance. If the current case were to be decided against JNJ (wouldn't be the fist time they lost) why wouldn't that impact the value of the franchise regardless of who owns it? Thanks for your insight. regards